Feed:All articles/Pretty: Difference between revisions

Jump to navigation Jump to search

Feed:All articles/Pretty (view source)

Revision as of 08:04, 13 June 2014

154 bytes added ,  13 June 2014
no edit summary
No edit summary
No edit summary
Line 22: Line 22:
         },
         },
         {
         {
             "timestamp" : "2013-10-19T15:24:19Z",
             "timestamp" : "2014-06-13T04:27:16Z",
             "briefDesignDescription" : "ISDN/hydralazine for blacks with HF",
             "briefDesignDescription" : "ISDN/hydralazine for blacks with HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa042934",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa042934",
             "pageid" : 41,
             "pageid" : 41,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa042934",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa042934",
             "trainingLevel" : "Student",
             "trainingLevel" : "Student\n}}",
             "citation" : "Taylor AL, <i>et al</i>. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". <i>The New England Journal of Medicine</i>. 2004. 351(20):2049-2057.",
             "citation" : "Taylor AL, <i>et al</i>. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". <i>The New England Journal of Medicine</i>. 2004. 351(20):2049-2057.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 490: Line 490:
         },
         },
         {
         {
             "timestamp" : "2013-07-19T09:39:28Z",
             "timestamp" : "2014-06-13T04:19:04Z",
             "briefDesignDescription" : "Ultrafiltration in decompensated HF",
             "briefDesignDescription" : "Ultrafiltration in decompensated HF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1210357",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1210357",
             "pageid" : 1356,
             "pageid" : 1356,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Bart BA, <i>et al</i>. \"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 367(24):2296-2304.",
             "citation" : "Bart BA, <i>et al</i>. \"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 367(24):2296-2304.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 634: Line 634:
         },
         },
         {
         {
             "timestamp" : "2013-07-19T09:42:35Z",
             "timestamp" : "2014-06-13T04:29:19Z",
             "briefDesignDescription" : "Carvedilol vs. metoprolol in HF",
             "briefDesignDescription" : "Carvedilol vs. metoprolol in HFrEF",
             "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13800-7/fulltext",
             "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13800-7/fulltext",
             "pageid" : 121,
             "pageid" : 121,
             "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf",
             "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Poole-Wilson PA, <i>et al</i>. \"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial\". <i>The Lancet</i>. 2003. 362(9377):7-13.",
             "citation" : "Poole-Wilson PA, <i>et al</i>. \"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial\". <i>The Lancet</i>. 2003. 362(9377):7-13.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Carvedilol Or Metoprolol European Trial",
             "expansion" : "Carvedilol Or Metoprolol European Trial",
             "briefResultsDescription" : "Carvedilol extends survival",
             "briefResultsDescription" : "Carvedilol extends survival in HFrEF",
             "published" : "2003-07-05",
             "published" : "2003-07-05",
             "pageName" : "COMET",
             "pageName" : "COMET",
Line 670: Line 670:
         },
         },
         {
         {
             "timestamp" : "2014-05-23T15:15:35Z",
             "timestamp" : "2014-06-13T04:30:42Z",
             "briefDesignDescription" : "Enalapril in severe HF",
             "briefDesignDescription" : "Enalapril in severe HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198706043162301",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198706043162301",
             "pageid" : 18,
             "pageid" : 18,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198706043162301",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198706043162301",
             "trainingLevel" : "Intern",
             "trainingLevel" : "Intern\n}}",
             "citation" : "CONSENSUS Trial Study Group. \"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study\". <i>The New England Journal of Medicine</i>. 1987. 316(23):1429-35.",
             "citation" : "CONSENSUS Trial Study Group. \"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study\". <i>The New England Journal of Medicine</i>. 1987. 316(23):1429-35.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Cooperative North Scandinavian Enalapril Survival Study",
             "expansion" : "Cooperative North Scandinavian Enalapril Survival Study",
             "briefResultsDescription" : "Enalapril ↓mortality in NYHA class IV HF",
             "briefResultsDescription" : "Enalapril ↓mortality in NYHA class IV HFrEF",
             "published" : "1987-06-04",
             "published" : "1987-06-04",
             "pageName" : "CONSENSUS",
             "pageName" : "CONSENSUS",
Line 688: Line 688:
         },
         },
         {
         {
             "timestamp" : "2013-08-23T20:51:32Z",
             "timestamp" : "2014-06-13T04:33:43Z",
             "briefDesignDescription" : "Carvedilol in HF",
             "briefDesignDescription" : "Carvedilol in HFrEF",
             "fulltexturl" : "http://circ.ahajournals.org/content/106/17/2194.full",
             "fulltexturl" : "http://circ.ahajournals.org/content/106/17/2194.full",
             "pageid" : 42,
             "pageid" : 42,
             "pdfurl" : "http://circ.ahajournals.org/content/106/17/2194.full.pdf",
             "pdfurl" : "http://circ.ahajournals.org/content/106/17/2194.full.pdf",
             "trainingLevel" : "Intern",
             "trainingLevel" : "Intern\n}}",
             "citation" : "Packer M, <i>et al</i>. \"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure\". <i>Circulation</i>. 2002. 106(17):2194-9.",
             "citation" : "Packer M, <i>et al</i>. \"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure\". <i>Circulation</i>. 2002. 106(17):2194-9.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Carvedilol Prospective Randomized Cumulative Survival",
             "expansion" : "Carvedilol Prospective Randomized Cumulative Survival",
             "briefResultsDescription" : "Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HF",
             "briefResultsDescription" : "Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF",
             "published" : "2002-10-22",
             "published" : "2002-10-22",
             "pageName" : "COPERNICUS",
             "pageName" : "COPERNICUS",
Line 706: Line 706:
         },
         },
         {
         {
             "timestamp" : "2013-05-07T14:56:04Z",
             "timestamp" : "2014-06-13T04:37:32Z",
             "briefDesignDescription" : "Rosuvastatin in ischemic HF",
             "briefDesignDescription" : "Rosuvastatin in ischemic HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0706201",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0706201",
             "pageid" : 524,
             "pageid" : 524,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Kjekshus J, <i>et al</i>. \"Rosuvastatin in Older Patients with Systolic Heart Failure\". <i>The New England Journal of Medicine</i>. 2007. 357(22):2248-61.",
             "citation" : "Kjekshus J, <i>et al</i>. \"Rosuvastatin in Older Patients with Systolic Heart Failure\". <i>The New England Journal of Medicine</i>. 2007. 357(22):2248-61.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Controlled Rosuvastatin Multinational Trial in Heart Failure",
             "expansion" : "Controlled Rosuvastatin Multinational Trial in Heart Failure",
             "briefResultsDescription" : "Statins confer no survival benefit but may reduce hospitalizations in ischemic CHF",
             "briefResultsDescription" : "Statins confer no survival benefit but may reduce hospitalizations in ischemic HFrEF",
             "published" : "2007-11-29",
             "published" : "2007-11-29",
             "pageName" : "CORONA",
             "pageName" : "CORONA",
Line 886: Line 886:
         },
         },
         {
         {
             "timestamp" : "2013-03-12T08:13:55Z",
             "timestamp" : "2014-06-13T04:45:33Z",
             "briefDesignDescription" : "ICD vs. medical therapy in HF",
             "briefDesignDescription" : "ICD vs. medical therapy in HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa033088",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa033088",
             "pageid" : 84,
             "pageid" : 84,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.",
             "citation" : "Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 904: Line 904:
         },
         },
         {
         {
             "timestamp" : "2013-10-24T01:13:09Z",
             "timestamp" : "2014-06-13T04:50:56Z",
             "briefDesignDescription" : "Digoxin in HF",
             "briefDesignDescription" : "Digoxin in HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199702203360801",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199702203360801",
             "pageid" : 89,
             "pageid" : 89,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.",
             "citation" : "Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 922: Line 922:
         },
         },
         {
         {
             "timestamp" : "2013-07-08T18:55:38Z",
             "timestamp" : "2014-06-13T05:00:40Z",
             "briefDesignDescription" : "Diuretic dosing in acute HF",
             "briefDesignDescription" : "Diuretic dosing in acute HF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1005419",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1005419",
             "pageid" : 1457,
             "pageid" : 1457,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419",
             "trainingLevel" : "Intern",
             "trainingLevel" : "Intern\n}}",
             "citation" : "Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.",
             "citation" : "Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 1,048: Line 1,048:
         },
         },
         {
         {
             "timestamp" : "2013-06-06T18:39:48Z",
             "timestamp" : "2014-06-13T05:16:42Z",
             "briefDesignDescription" : "Eplerenone in HF",
             "briefDesignDescription" : "Eplerenone in HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009492",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009492",
             "pageid" : 120,
             "pageid" : 120,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Zannad F, <i>et al</i>. \"Eplerenone in patients with systolic heart failure and mild symptoms\". <i>The New England Journal of Medicine</i>. 2011. 364(1):11-21.",
             "citation" : "Zannad F, <i>et al</i>. \"Eplerenone in patients with systolic heart failure and mild symptoms\". <i>The New England Journal of Medicine</i>. 2011. 364(1):11-21.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure",
             "expansion" : "Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure",
             "briefResultsDescription" : "Eplerenone reduces CV deaths and CHF hospitalizations",
             "briefResultsDescription" : "Eplerenone reduces CV deaths and HF hospitalizations",
             "published" : "2011-01-06",
             "published" : "2011-01-06",
             "pageName" : "EMPHASIS-HF",
             "pageName" : "EMPHASIS-HF",
Line 1,066: Line 1,066:
         },
         },
         {
         {
             "timestamp" : "2014-05-15T02:22:45Z",
             "timestamp" : "2014-06-13T05:20:42Z",
             "briefDesignDescription" : "Eplerenone post-MI with HF",
             "briefDesignDescription" : "Eplerenone post-MI with HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030207",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030207",
             "pageid" : 16,
             "pageid" : 16,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Pitt B, <i>et al</i>. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2003. 348(14):1309-21.",
             "citation" : "Pitt B, <i>et al</i>. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2003. 348(14):1309-21.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study",
             "expansion" : "Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study",
             "briefResultsDescription" : "Mortality benefit of eplerenone post MI with CHF",
             "briefResultsDescription" : "Mortality benefit of eplerenone post MI with HFrEF",
             "published" : "2003-04-03",
             "published" : "2003-04-03",
             "pageName" : "EPHESUS",
             "pageName" : "EPHESUS",
Line 1,084: Line 1,084:
         },
         },
         {
         {
             "timestamp" : "2013-07-08T17:33:52Z",
             "timestamp" : "2014-06-13T05:31:57Z",
             "briefDesignDescription" : "PA catheters in acute HF management",
             "briefDesignDescription" : "PA catheters in acute HF management",
             "fulltexturl" : null,
             "fulltexturl" : null,
             "pageid" : 1407,
             "pageid" : 1407,
             "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf",
             "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Binanay C, <i>et al</i>. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". <i>JAMA</i>. 2005. 294(13):1625-1633.",
             "citation" : "Binanay C, <i>et al</i>. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". <i>JAMA</i>. 2005. 294(13):1625-1633.",
             "subspecialties" : "Cardiology;Critical Care",
             "subspecialties" : "Cardiology;Critical Care",
Line 1,156: Line 1,156:
         },
         },
         {
         {
             "timestamp" : "2013-06-19T14:58:18Z",
             "timestamp" : "2014-06-13T05:39:33Z",
             "briefDesignDescription" : "Tolvaptan in HF",
             "briefDesignDescription" : "Tolvaptan in acute HF if HFrEF",
             "fulltexturl" : null,
             "fulltexturl" : null,
             "pageid" : 1345,
             "pageid" : 1345,
             "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf",
             "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Konstam MA, <i>et al</i>. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". <i>The Journal of the American Medical Association</i>. 2007. 297(12):1319-1331.",
             "citation" : "Konstam MA, <i>et al</i>. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". <i>The Journal of the American Medical Association</i>. 2007. 297(12):1319-1331.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 1,282: Line 1,282:
         },
         },
         {
         {
             "timestamp" : "2013-06-30T15:37:01Z",
             "timestamp" : "2014-06-13T05:49:27Z",
             "briefDesignDescription" : "Lisinopril in acute MI",
             "briefDesignDescription" : "Lisinopril in acute MI",
             "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract",
             "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract",
Line 1,294: Line 1,294:
             "published" : "1994-05-07",
             "published" : "1994-05-07",
             "pageName" : "GISSI-3",
             "pageName" : "GISSI-3",
             "diseases" : "Acute Coronary Syndrome;Heart Failure;Myocardial Infarction",
             "diseases" : "Acute Coronary Syndrome;Myocardial Infarction",
             "abbreviation" : "GISSI-3",
             "abbreviation" : "GISSI-3",
             "title" : "Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction",
             "title" : "Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction",
Line 1,372: Line 1,372:
         },
         },
         {
         {
             "timestamp" : "2013-07-08T18:55:53Z",
             "timestamp" : "2014-06-13T05:59:23Z",
             "briefDesignDescription" : "IABP in MI and cardiogenic shock",
             "briefDesignDescription" : "IABP in MI and cardiogenic shock",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208410",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208410",
Line 1,384: Line 1,384:
             "published" : "2012-10-10",
             "published" : "2012-10-10",
             "pageName" : "IABP-SHOCK II",
             "pageName" : "IABP-SHOCK II",
             "diseases" : "Acute Coronary Syndrome;Heart Failure;Shock;Myocardial Infarction",
             "diseases" : "Acute Coronary Syndrome;Myocardial Infarction;Shock",
             "abbreviation" : "IABP-SHOCK II",
             "abbreviation" : "IABP-SHOCK II",
             "title" : "Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock",
             "title" : "Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock",
Line 1,570: Line 1,570:
         },
         },
         {
         {
             "timestamp" : "2014-05-13T22:31:56Z",
             "timestamp" : "2014-06-13T06:00:39Z",
             "briefDesignDescription" : "CRT in HFrEF with QRS ≥130 msec and mild symptoms",
             "briefDesignDescription" : "CRT in HFrEF with QRS ≥130 msec and mild symptoms",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0906431",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0906431",
             "pageid" : 1780,
             "pageid" : 1780,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Moss AJ, <i>et al</i>. \"Cardiac-resynchronization therapy for the prevention of heart-failure events\". <i>The New England Journal of Medicine</i>. 2009. 361(14):1329-1338.",
             "citation" : "Moss AJ, <i>et al</i>. \"Cardiac-resynchronization therapy for the prevention of heart-failure events\". <i>The New England Journal of Medicine</i>. 2009. 361(14):1329-1338.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 1,588: Line 1,588:
         },
         },
         {
         {
             "timestamp" : "2013-07-04T09:24:31Z",
             "timestamp" : "2014-06-13T06:03:11Z",
             "briefDesignDescription" : "ICD in post-MI patients with HF",
             "briefDesignDescription" : "ICD in post-MI patients with HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa013474",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa013474",
             "pageid" : 385,
             "pageid" : 385,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Moss AJ, <i>et al</i>. \"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2002. 346(12):877-883.",
             "citation" : "Moss AJ, <i>et al</i>. \"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2002. 346(12):877-883.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 1,642: Line 1,642:
         },
         },
         {
         {
             "timestamp" : "2013-08-02T19:02:32Z",
             "timestamp" : "2014-06-13T06:05:38Z",
             "briefDesignDescription" : "Metoprolol in HF",
             "briefDesignDescription" : "Metoprolol in HFrEF",
             "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402",
             "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402",
             "pageid" : 130,
             "pageid" : 130,
             "pdfurl" : "",
             "pdfurl" : "",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Fagerberg B, <i>et al</i>. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". <i>The Lancet</i>. 1999. 353(9169):2001-7.",
             "citation" : "Fagerberg B, <i>et al</i>. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". <i>The Lancet</i>. 1999. 353(9169):2001-7.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure",
             "expansion" : "Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure",
             "briefResultsDescription" : "Metoprolol improves survival in NYHA II-IV CHF",
             "briefResultsDescription" : "Metoprolol improves survival in NYHA II-IV HFrEF",
             "published" : "1999-06-12",
             "published" : "1999-06-12",
             "pageName" : "MERIT-HF",
             "pageName" : "MERIT-HF",
Line 1,930: Line 1,930:
         },
         },
         {
         {
             "timestamp" : "2014-06-06T14:28:19Z",
             "timestamp" : "2014-06-13T06:58:38Z",
             "briefDesignDescription" : "Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM",
             "briefDesignDescription" : "Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801317",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801317",
Line 2,398: Line 2,398:
         },
         },
         {
         {
             "timestamp" : "2014-05-16T14:31:13Z",
             "timestamp" : "2014-06-13T06:10:06Z",
             "briefDesignDescription" : "Spironolactone in HF",
             "briefDesignDescription" : "Spironolactone in HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199909023411001",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199909023411001",
             "pageid" : 11,
             "pageid" : 11,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001",
             "trainingLevel" : "Intern",
             "trainingLevel" : "Intern\n}}",
             "citation" : "Pitt B, <i>et al</i>. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". <i>New England Journal of Medicine</i>. 1999. 341:709-717.",
             "citation" : "Pitt B, <i>et al</i>. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". <i>New England Journal of Medicine</i>. 1999. 341(10):709-717.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Randomized Aldactone Evaluation Study",
             "expansion" : "Randomized Aldactone Evaluation Study",
             "briefResultsDescription" : "Spironolactone reduces all-cause mortality by 30% in severe CHF.",
             "briefResultsDescription" : "Spironolactone reduces all-cause mortality by 30% in severe HFrEF",
             "published" : "1999-09-02",
             "published" : "1999-09-02",
             "pageName" : "RALES",
             "pageName" : "RALES",
Line 2,632: Line 2,632:
         },
         },
         {
         {
             "timestamp" : "2013-06-30T15:43:54Z",
             "timestamp" : "2014-06-13T06:16:05Z",
             "briefDesignDescription" : "Captopril in MI with LV dysfunction",
             "briefDesignDescription" : "Captopril in MI with LV dysfunction",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199209033271001",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199209033271001",
             "pageid" : 150,
             "pageid" : 150,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199209033271001",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199209033271001",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Pfeffer MA, <i>et al</i>. \"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial\". <i>The New England Journal of Medicine</i>. 1992. 327(10):669-677.",
             "citation" : "Pfeffer MA, <i>et al</i>. \"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial\". <i>The New England Journal of Medicine</i>. 1992. 327(10):669-677.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 2,650: Line 2,650:
         },
         },
         {
         {
             "timestamp" : "2013-04-09T23:23:32Z",
             "timestamp" : "2014-06-13T06:22:51Z",
             "briefDesignDescription" : "Amiodarone or ICD in severe HF",
             "briefDesignDescription" : "Amiodarone or ICD in severe HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa043399",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa043399",
             "pageid" : 40,
             "pageid" : 40,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043399",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043399",
             "trainingLevel" : "Intern",
             "trainingLevel" : "Intern\n}}",
             "citation" : "Bardy GH, <i>et al</i>. \"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure\". <i>The New England Journal of Medicine</i>. 2005. 252(3):225-37.",
             "citation" : "Bardy GH, <i>et al</i>. \"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure\". <i>The New England Journal of Medicine</i>. 2005. 252(3):225-37.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Sudden Cardiac Death in Heart Failure Trial",
             "expansion" : "Sudden Cardiac Death in Heart Failure Trial",
             "briefResultsDescription" : "ICD reduces mortality by 23% in class II-III HF",
             "briefResultsDescription" : "ICD reduces mortality by 23% in class II-III HFrEF",
             "published" : "2005-01-20",
             "published" : "2005-01-20",
             "pageName" : "SCD-HeFT",
             "pageName" : "SCD-HeFT",
Line 2,758: Line 2,758:
         },
         },
         {
         {
             "timestamp" : "2013-03-13T05:25:09Z",
             "timestamp" : "2014-06-13T07:07:04Z",
             "briefDesignDescription" : "Enalapril in moderate-severe HF",
             "briefDesignDescription" : "Enalapril in moderate-severe HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199108013250501",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199108013250501",
             "pageid" : 394,
             "pageid" : 394,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Yusuf S, <i>et al</i>. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):293-302.",
             "citation" : "Yusuf S, <i>et al</i>. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):293-302.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Studies of Left Ventricular Dysfunction",
             "expansion" : "Studies of Left Ventricular Dysfunction",
             "briefResultsDescription" : "Enalapril reduces mortality and HF hospitalizations in HF",
             "briefResultsDescription" : "Enalapril reduces mortality and HF hospitalizations in HFrEF",
             "published" : "1991-08-01",
             "published" : "1991-08-01",
             "pageName" : "SOLVD",
             "pageName" : "SOLVD",
Line 2,830: Line 2,830:
         },
         },
         {
         {
             "timestamp" : "2013-06-18T17:07:32Z",
             "timestamp" : "2014-06-13T06:39:16Z",
             "briefDesignDescription" : "CABG in ischemic HF",
             "briefDesignDescription" : "CABG in ischemic HFrEF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1100356",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1100356",
             "pageid" : 471,
             "pageid" : 471,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Velazquez EJ, <i>et al</i>. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". <i>The New England Journal of Medicine</i>. 2011. 354(17):1607-1616.",
             "citation" : "Velazquez EJ, <i>et al</i>. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". <i>The New England Journal of Medicine</i>. 2011. 354(17):1607-1616.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 3,082: Line 3,082:
         },
         },
         {
         {
             "timestamp" : "2014-06-09T01:55:10Z",
             "timestamp" : "2014-06-13T04:18:03Z",
             "briefDesignDescription" : "ISDN/hydralazine in HF",
             "briefDesignDescription" : "ISDN/hydralazine in HF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198606123142404",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198606123142404",
             "pageid" : 155,
             "pageid" : 155,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198606123142404",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198606123142404",
             "trainingLevel" : "student",
             "trainingLevel" : "student\n}}",
             "citation" : "Cohn JN, <i>et al</i>. \"Effect of vasodilator therapy on mortality in chronic congestive heart failure\". <i>The New England Journal of Medicine</i>. 1986. 314(24):1547-52.",
             "citation" : "Cohn JN, <i>et al</i>. \"Effect of vasodilator therapy on mortality in chronic congestive heart failure\". <i>The New England Journal of Medicine</i>. 1986. 314(24):1547-52.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
Line 3,154: Line 3,154:
         },
         },
         {
         {
             "timestamp" : "2013-03-13T05:28:05Z",
             "timestamp" : "2014-06-13T07:33:06Z",
             "briefDesignDescription" : "Valsartan in HF",
             "briefDesignDescription" : "Valsartan in HF",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010713",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010713",
             "pageid" : 20,
             "pageid" : 20,
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa010713",
             "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa010713",
             "trainingLevel" : "Resident",
             "trainingLevel" : "Resident\n}}",
             "citation" : "Cohn JN, <i>et al</i>. \"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure\". <i>New England Journal of Medicine</i>. 2001. 345(23):1667-75.",
             "citation" : "Cohn JN, <i>et al</i>. \"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure\". <i>New England Journal of Medicine</i>. 2001. 345(23):1667-75.",
             "subspecialties" : "Cardiology",
             "subspecialties" : "Cardiology",
             "expansion" : "Valsartan Heart Failure Trial",
             "expansion" : "Valsartan Heart Failure Trial",
             "briefResultsDescription" : "No mortality benefit of Valsartan in NYHA II-IV CHF",
             "briefResultsDescription" : "No mortality benefit of valsartan in NYHA II-IV HF",
             "published" : "2001-12-06",
             "published" : "2001-12-06",
             "pageName" : "Val-HeFT",
             "pageName" : "Val-HeFT",
Line 3,172: Line 3,172:
         },
         },
         {
         {
             "timestamp" : "2013-07-01T13:20:27Z",
             "timestamp" : "2014-06-13T06:41:14Z",
             "briefDesignDescription" : "Valsartan vs. captopril in MI with LV dysfunction",
             "briefDesignDescription" : "Valsartan vs. captopril in MI with LV dysfunction",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa032292",
             "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa032292",
WJCBot
Bots, editor, reviewer, Administrators
13,951

edits

Retrieved from "http://www.wikijournalclub.org/wiki/Special:MobileDiff/12905"

Navigation menu